Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64.
The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion. Operational growth was 3.9%, and adjusted operational growth was 4.0%.
After good earnings results, Cantor Fitzgerald remains positive on Johnson & Johnson's stock.
The analyst writes that numerous positive data releases and approvals for new uses of existing drugs are anticipated to boost Johnson & Johnson stock.
Cantor notes that the market is undervaluing the potential peak sales of Taris, Carvykti, Mariposa, nipocalimab, JNJ-2113, and other products.
Additionally, the pharma/medtech giant aims to lead in Innovative Medicines and MedTech, seeking to become the top player in these fields.
While the market sees Johnson & Johnson as strong in its sectors, it doesn't yet perceive it as the best.
Cantor maintains the Overweight rating with a price target of $215.
Also Read: Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population.
Goldman Sachs noted several variances in pharmaceutical performance compared to their expectations. Stelara fell short by 5% compared to GS estimates and 4% compared to consensus. Xarelto was notably below expectations, with a difference of 9% and 7%, respectively.
However, Tremfya showed a slight upside, surpassing expectations by 3% and 2%.
The Multiple myeloma franchise performed well in the oncology sector, with Darzalex achieving a strong 22% year-on-year growth.
Carvykti, however, was disappointed with flat sequential growth and a decline of 16% compared to GS estimates and 13% compared to consensus. Management attributed this to the phasing of orders, expecting order trends to improve, especially with the recent label expansion.
Price Action: JNJ shares are down 0.13% at $144.26 on the last check Wednesday.
Photo via Wikimedia Commons
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64.
週二，強生公司（紐約證券交易所代碼：JNJ）公佈的第一季度調整後每股收益爲2.71美元，同比增長12.4％，超過市場普遍的2.64美元。
The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion. Operational growth was 3.9%, and adjusted operational growth was 4.0%.
這家制藥巨頭報告的銷售額爲213.8億美元，同比增長2.3％，幾乎與213.9億美元的共識持平。運營增長3.9％，調整後的運營增長4.0％。
After good earnings results, Cantor Fitzgerald remains positive on Johnson & Johnson's stock.
在取得良好的盈利業績之後，坎託·菲茨傑拉德對強生公司的股票仍然持樂觀態度。
The analyst writes that numerous positive data releases and approvals for new uses of existing drugs are anticipated to boost Johnson & Johnson stock.
這位分析師寫道，大量積極的數據發佈和現有藥物新用途的批准預計將提振強生公司的股票。
Cantor notes that the market is undervaluing the potential peak sales of Taris, Carvykti, Mariposa, nipocalimab, JNJ-2113, and other products.
坎托爾指出，市場低估了Taris、Carvykti、Mariposa、nipocalimab、JNJ-2113 和其他產品的潛在峯值銷售額。
Additionally, the pharma/medtech giant aims to lead in Innovative Medicines and MedTech, seeking to become the top player in these fields.
此外，這家制藥/醫療科技巨頭的目標是在創新藥物和醫療技術領域處於領先地位，尋求成爲這些領域的頂級參與者。
While the market sees Johnson & Johnson as strong in its sectors, it doesn't yet perceive it as the best.
儘管市場認爲強生公司在其行業中表現強勁，但尚未將其視爲最好的。
Cantor maintains the Overweight rating with a price target of $215.
坎托維持增持評級，目標股價爲215美元。
Also Read: Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population.
另請閱讀：強生公司的Carvykti領先於布里斯托爾·邁爾斯的競爭對手血癌療法，獲得美國食品藥品管理局的批准，適用於更多人群。
Goldman Sachs noted several variances in pharmaceutical performance compared to their expectations. Stelara fell short by 5% compared to GS estimates and 4% compared to consensus. Xarelto was notably below expectations, with a difference of 9% and 7%, respectively.
高盛指出，與預期相比，製藥業績存在一些差異。與GS的估計相比，Stelara下跌了5％，與共識相比下跌了4％。Xarelto明顯低於預期，差異分別爲9％和7％。
However, Tremfya showed a slight upside, surpassing expectations by 3% and 2%.
但是，Tremfya略有上漲，比預期高出3％和2％。
The Multiple myeloma franchise performed well in the oncology sector, with Darzalex achieving a strong 22% year-on-year growth.
多發性骨髓瘤特許經營權在腫瘤學領域表現良好，Darzalex實現了22％的強勁同比增長。
Carvykti, however, was disappointed with flat sequential growth and a decline of 16% compared to GS estimates and 13% compared to consensus. Management attributed this to the phasing of orders, expecting order trends to improve, especially with the recent label expansion.
但是，Carvykti對連續增長持平感到失望，與GS的估計相比下降了16％，與市場預期相比下降了13％。管理層將此歸因於訂單的分階段，預計訂單趨勢將有所改善，尤其是在最近的品牌擴張中。
Price Action: JNJ shares are down 0.13% at $144.26 on the last check Wednesday.
價格走勢：在週三的最後一次支票中，JNJ股價下跌0.13％，至144.26美元。
Photo via Wikimedia Commons
照片來自維基共享資源
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧